Hey all. I put together an AF-treatment power-point presentation for a group of primary care doctors, ER doctors and others this morning. The title of the talk is 2011 Update in the treatment of AF. The focus of the presentation will be five aspects of AF treatment: The best tool to treat AF A better […]
Search: “rivaroxaban”
We found 41 results for your search.
You can mark August 2011 as an amazing month for news in the treatment of atrial fibrillation (AF). In this post, I will attempt to share what I have learned about the two new blood-thinning drugs, apixaban and rivaroxaban–both Factor Xa inhibitors. (Disclaimer: this is not a book chapter, rather a blog post from a […]
I recently came across a very important blog post on the use of the novel new blood-thinner, dabigatran (Pradaxa). Fellow Kentucky cardiologist, and frequent TheHeart.org contributor, Dr. Melissa Walton-Shirley wrote this very detailed case presentation involving a cantankerous non-compliant rural patient with AF (atrial fibrillation) that sustained a stroke while “taking†dabigatran. Dr. Walton-Shirley details […]
It’s been awhile since I have written about the treatment of atrial fibrillation (AF). I would like to remedy this by sharing a few thoughts on three recent stories about AF: one involved a soon-to-be-approved blood-thinning drug; the second highlighted a potentially exciting new device for ablating AF, and the third story irresponsibly sensationalized the […]
Over the past 16 years, the Boston AF Symposium has earned a reputation for excellence. Dr Jeremy Ruskin, the meeting’s senior director and founder, squeezes more learning into three days than would seem possible. It’s a mystery how he gets that many of Earth’s greatest AF-doctors to Boston in January. Though this year’s edition coincided […]
Atrial fibrillation (AF) is the most common heart rhythm disorder–by a long shot. It affects–and often afflicts–millions. AF is the most common heart-related reason for hospital admission. In America, more than 1 in 4 individuals will have AF in their lifetime. Yet even more remarkable than the vastness of AF’s prevalence is its diversity. AF […]
I remember in high school, as an assignment, I wrote a letter to a prominent business person. I will try it again. In 2010, this would be an e-letter. To: J Martin CarrollCEO of Boehringer Ingelheim Corporation: The makers of the recently-released exciting new oral blood-thinner, dabigatran (Pradaxa). Dear Sir, To start off on a positive […]
The dabigatran party isn’t even cleaned-up yet, when another warfarin competitor has hit the press wires. As reported on Cardiobrief from a Bayer press release, Rivaroxaban (Xarelto) was as effective as warfarin in stroke prevention in patients’ with AF. A composite of major and minor bleeding events were also similar to warfarin. Rivaroxaban is a […]